← All trials
NCT06084104
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 17, 2023
- Primary completion
- Jan 31, 2024
- Completion date
- Feb 29, 2024
- First posted
- Oct 16, 2023
- Last posted
- Nov 13, 2023
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.Lead sponsor
- Orlando Clinical Research CenterOverall official - principal investigator
- Orlando Clinical Research CenterOfficial
- Texas Liver InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.